Michelle Morrow PhD

Michelle has over 10 years’ industry experience as a scientific leader of immuno-oncology projects from target validation through to clinical development. She joined F-star in 2017 to establish the Preclinical Translational Pharmacology department. Prior to joining F-star, Michelle was a project and team leader at Medimmune Ltd (formerly Cambridge Antibody Technology (CAT)) where she successfully established many preclinical model systems and led a number of research projects, including a role as discovery project leader for durvalumab (Imfinzi™). Michelle holds a PhD in Immunology from the University of Cambridge and performed post-doctoral research into childhood Leukaemia at the Institute of Child Health, London.